Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies to develop T-cell receptors, tumor-infiltrating lymphocytes, and chimeric antigen receptor-based cell therapies.

The 70,000-sq-ft production facilities house advanced capabilities for cell therapy manufacturing. In addition to cell processing equipment and manufacturing processes necessary to expand and reengineer patient immune cells, the center will integrate advanced data and analytics approaches that enable a completely digital manufacturing process. This includes real-time data feedback and batch monitoring, as well as analytical capabilities that enable artificial intelligence and machine-learning applications to enable faster process improvements.

Lyell's Lyfe center is the first cell therapy manufacturing facility to support digital manufacturing capabilities from Amazon Web Services, including cloud computing, Internet of Things (IoT), and advanced analytics.